54,266 Shares in Royalty Pharma PLC $RPRX Acquired by WBI Investments LLC

WBI Investments LLC purchased a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 54,266 shares of the biopharmaceutical company’s stock, valued at approximately $1,915,000.

A number of other large investors also recently modified their holdings of RPRX. Danske Bank A S acquired a new position in shares of Royalty Pharma during the third quarter worth $17,134,000. Caitong International Asset Management Co. Ltd acquired a new stake in Royalty Pharma in the third quarter valued at $100,000. Dark Forest Capital Management LP acquired a new stake in Royalty Pharma in the third quarter valued at $7,925,000. XTX Topco Ltd purchased a new stake in Royalty Pharma during the 3rd quarter worth about $5,121,000. Finally, State Street Corp lifted its holdings in Royalty Pharma by 0.8% during the 3rd quarter. State Street Corp now owns 10,272,753 shares of the biopharmaceutical company’s stock worth $362,423,000 after buying an additional 77,815 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on RPRX. TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Weiss Ratings upgraded Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, February 12th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. UBS Group upgraded shares of Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target on the stock in a research note on Friday, January 30th. Finally, Morgan Stanley reissued an “overweight” rating and set a $61.00 price objective on shares of Royalty Pharma in a report on Thursday, February 12th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and an average target price of $48.67.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $46.11 on Wednesday. The firm’s fifty day moving average price is $43.49 and its 200 day moving average price is $39.73. Royalty Pharma PLC has a 1-year low of $29.66 and a 1-year high of $47.86. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40. The firm has a market cap of $26.60 billion, a price-to-earnings ratio of 34.16 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The company had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. On average, sell-side analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Friday, February 20th were issued a dividend of $0.235 per share. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend was Friday, February 20th. Royalty Pharma’s dividend payout ratio is currently 69.63%.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $41.09, for a total value of $821,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Terrance P. Coyne sold 34,791 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $46.78, for a total value of $1,627,522.98. Following the transaction, the chief financial officer owned 45,761 shares in the company, valued at $2,140,699.58. The trade was a 43.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 568,150 shares of company stock valued at $23,366,062. 18.90% of the stock is owned by insiders.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.